Farxiga demonstrated consistent benefit regardless of heart

Two new analyses from the DELIVER Phase III trial presented at European Society of Cardiology’s Heart Failure 2023 congress in Prague, Czech Republic support the consistent benefits of Farxiga regardless of heart failure (HF) duration1 and across the spectrum of cardiovascular, renal and metabolic (CVRM) ...

Related Keywords

United Kingdom , Prague , Praha , Hlavníesto , Czech Republic , Cambridge , Cambridgeshire , United States , Sweden , American , Coll Cardiol , Scott Solomon , J Geriatr Cardiol , National Institute Of Diabetes , Company On Twitter , Astrazeneca , Professor Of Medicine At Harvard Medical School , Nasdaq , A Report From The American Heart Association , Centers For Disease , European Society Of Cardiology Heart Failure , European Society , Heart Failure , Harvard Medical School , Principal Investigator , Executive Vice President , Biopharmaceuticals Business Unit , Kansas City Cardiomyopathy Questionnaire , Dapagliflozin And Prevention , Rare Diseases , Report From , American Heart , Eurj Heart , Kidney Disease , Improving Global Outcomes , Kidney Int , Res Int , Global Burden , Disease Study , American College , American Heart Association Joint Committee , Clinical Practice , Eur Heart , Disease Control , Kidney Diseases ,